141 related articles for article (PubMed ID: 32752909)
1. Identification of benzimidazole containing 4
Lakshmanan K; Byran G
J Recept Signal Transduct Res; 2021 Apr; 41(2):153-158. PubMed ID: 32752909
[TBL] [Abstract][Full Text] [Related]
2. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors.
Celik İ; Ayhan-Kılcıgil G; Guven B; Kara Z; Gurkan-Alp AS; Karayel A; Onay-Besikci A
Eur J Med Chem; 2019 Jul; 173():240-249. PubMed ID: 31009910
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of novel benzimidazole derivatives as sphingosine kinase 1 inhibitor.
Khairat SHM; Omar MA; Ragab FAF; Roy S; Turab Naqvi AA; Abdelsamie AS; Hirsch AKH; Galal SA; Hassan MI; El Diwani HI
Arch Pharm (Weinheim); 2021 Sep; 354(9):e2100080. PubMed ID: 34128259
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and molecular docking studies of new furochromone derivatives as p38α MAPK inhibitors targeting human breast cancer MCF-7 cells.
Amin KM; Syam YM; Anwar MM; Ali HI; Abdel-Ghani TM; Serry AM
Bioorg Med Chem; 2017 Apr; 25(8):2423-2436. PubMed ID: 28291685
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Evaluation of 2,3,4-Triaryl-1,2,4-oxadiazol-5-ones as p38 MAPK Inhibitors.
Romeo R; Giofrè SV; Chiacchio MA; Veltri L; Celesti C; Iannazzo D
Molecules; 2021 Mar; 26(6):. PubMed ID: 33804659
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306
[TBL] [Abstract][Full Text] [Related]
11. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
Kale MA; Sonwane GM
Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties.
Somakala K; Tariq S; Amir M
Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, p38 kinase inhibitory and anti-inflammatory activity of new substituted benzimidazole derivatives.
Kulkarni RG; Laufer SA; M CV; Garlapati A
Med Chem; 2013 Feb; 9(1):91-9. PubMed ID: 22946527
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors.
Hauser DR; Scior T; Domeyer DM; Kammerer B; Laufer SA
J Med Chem; 2007 May; 50(9):2060-6. PubMed ID: 17411025
[TBL] [Abstract][Full Text] [Related]
15. Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease.
Pinsetta FR; Taft CA; de Paula da Silva CH
J Biomol Struct Dyn; 2014; 32(7):1047-63. PubMed ID: 23805842
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer.
Bistrović A; Krstulović L; Harej A; Grbčić P; Sedić M; Koštrun S; Pavelić SK; Bajić M; Raić-Malić S
Eur J Med Chem; 2018 Jan; 143():1616-1634. PubMed ID: 29133046
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of 2-phenyl benzimidazole derivatives as VEGFR-2 inhibitors with anti-breast cancer activity.
Mostafa AS; Gomaa RM; Elmorsy MA
Chem Biol Drug Des; 2019 Apr; 93(4):454-463. PubMed ID: 30393973
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors.
Kulkarni RG; Laufer S; Mangannavar C; Garlapati A
Med Chem; 2013 Mar; 9(2):213-21. PubMed ID: 22946566
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, p38α MAP kinase inhibition, anti-inflammatory activity, and molecular docking studies of 1,2,4-triazole-based benzothiazole-2-amines.
Tariq S; Alam O; Amir M
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700304. PubMed ID: 29611883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]